Table 2.
Summary of druggability and clinical development activity for multiple myeloma associated with causal associations on Mendelian randomization analysis
| Target | Status | Compound name | Molecule type | Action type | Clinical development activities |
|---|---|---|---|---|---|
| NAMPT | In development |
DAPORINADb (CHEMBL566757) |
Small molecule | Inhibitor | Phase I/II trials: cutaneous T-cell Lymphoma, melanoma, B-cell chronic lymphocytic leukemia |
| In development |
TEGLARINADb (CHEMBL1181731) |
Small molecule | Inhibitor | Phase I trial: lymphoma | |
| In development | ATG-019c | Small molecule | Inhibitor | Phase I trial: non-Hodgkin's lymphoma (NCT04281420) | |
| In development | KPT-9274c | Small molecule | Inhibitor | Phase I trial: non-Hodgkin's lymphoma, acute myeloid leukemia (NCT02702492) | |
| TIE1 | In development |
CP-459632b (CHEMBL3545300) |
Small molecule | Inhibitor | - |
| FSTL1 | Druggablea | - | Antibodya | - | - |
| CBR1 | Druggablea | - | Small moleculea | - | - |
| GZMB | Druggablea | - | Small moleculea | - | - |
| PDE4D | In development |
ZATOLMILASTb (CHEMBL4541964) |
Small molecule | Inhibitor | Phase II trials: Alzheimer’s disease, fragile X syndrome, depression |
| GPC1 | Druggablea | - | Antibodya | - | - |
| C1QC | Druggablea | - | Antibodya | - | - |
| FCGR3B | In development |
IMGATUZUMABb (CHEMBL2109389) |
Antibody | Cross-linking agent | Phase I/II trials: colorectal neoplasms, head and neck neoplasms, non-small-cell lung |
| NCF2 | Not currently listed as druggable | - | - | - | - |
| PTPN4 | Not currently listed as druggable | - | - | - | - |
| SOCS3 | Not currently listed as druggable | - | - | - | - |
| PAFAH1B2 | Not currently listed as druggable | - | - | - | - |
C1QC complement C1q subcomponent subunit C, CBR1 carbonyl reductase 1, FCGR3B Fc-gamma receptor III-B, FSTL1 follistatin-related protein 1, FDR false discovery rate, GPC1 glypican 1, GZMB granzyme B, NAMPT nicotinamide phosphoribosyl transferase, NCF2 neutrophil cytosol factor 2, PAFAH1B2 platelet-activating factor acetyl hydrolase IB subunit beta, PDE4D cAMP-specific 3',5'-cyclic phosphodiesterase 4D, PTPN4 protein tyrosine phosphatase non-receptor type 4, SOCS3 suppressor of cytokine signaling 3, TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1, SNP single nucleotide polymorphism
aData from druggable list [15]
bData from ChEMBL release 27 [16] (compound ID in brackets)
cData from https://www.ClinicalTrials.gov (clinical trial ID in brackets)